FDA Cites India API Facility For CGMP Violations

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-10-07-2015
Volume 11
Issue 10

The agency cited Pan Drugs Limited with improper cleaning of facilities and equipment.

FDA issued a warning letter to an API manufacturer, Pan Drugs Limited (Vadodara, India), on Sept. 2, 2015, citing improper maintenance, repair, and cleaning of buildings used to manufacturer APIs. FDA investigators observed holes in the walls and roof that gave pigeons access to areas where production equipment was used. They also observed gaps and holes in outside walls near piping and air ducts that could allow contaminates to enter the facility. The company also failed to maintain equipment used to manufacture APIs, according to FDA. Investigators “observed rust, dirt, lubrication leaks, and exposed insulation material on and around open drug manufacturing equipment.”

The company was also cited for failure to maintain complete analytical testing data. FDA says that for a specific lot, analytical testing documentation provided to the agency indicated that no heavy metals analysis was performed; the name of the analyst who performed the residual solvents analysis was not included; and no second person reviewed the documents for accuracy, completeness, and compliance with established standards.

FDA is recommending the company obtain a third-party consultant to assess the firm’s operation and that the company contact the Center for Drug Evaluation and Research’s Drug Shortages Staff for help bringing the company into compliance to minimize the affect on the drug supply.

Source: FDA

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes